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Abstract
Background: Hepatitis B virus (HBV) infection is one of the most common public health problems worldwide. Over one
million people die annually of  HBV- related chronic liver disease. Maternal to fetal transmission from chronic carriers exceeds
90% and accounts for up to 40% of  the world’s chronic carriers in endemic areas.
Methods: This was a descriptive study which involved Serial recruitment of 836 women attending the antenatal clinic at a
health facility in Cross-River State, Nigeria from 1st January to 30th June 2010. HBsAg screening was done using an ELISA
test.
Results: Fifty five (6.6%) of  the 836 women screened tested positive for HBsAg. The mean age and parity of  sero-positive
subjects was 26.9 ±5.0 (range 18-38 years) and 2.2±1.2 (0 to 5) respectively. The prevalence was more in women who were
farmers (29.1%) and those with either none or low level of formal education (67.2%).
Conclusion: Sero-prevalence of  6.6% among pregnant women is reported. Women education, economic empowerment
and public enlightenment programmes focused on modification of risky social lifestyle is recommended. Efforts to promote
routine screening of pregnant women, immunization and vaccination of infants should be sustained.
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Hepatitis B virus (HBV) infection is one of the most
common public health problems worldwide. It has
been estimated that 350 million people world-wide
are chronic carriers of hepatitis B virus1. These
chronically infected persons are at a high risk of
death from liver cirrhosis and hepatocellular
carcinoma2, 3. Over one million people die annually
of  HBV-related chronic liver disease4.
In Europe and America, chronic carriers of
HBV are found in less than 2% of the population.
The sero-prevalence rates of 0.44%, 1.4%, 10% were
reported in Netherland, Germany and Hong Kong
respectively. Studies done in different regions of
Turkey showed that the prevalence rates range from
2% to 14.3%2. In Africa, it is believed that more
than half of the population becomes infected during
their reproductive lifetime and about 8% of
inhabitants become chronic carriers2.
Hepatitis B virus is transmitted primarily
through parenteral and sexual exposure to HBsAg
positive blood or other body fluid5. This double
stranded DNA virus belonging to hepadnaviridae
family is of clinical significance to the Obstetrician.
This is due to the fact that viral hepatitis during
pregnancy is not only associated with the high risk
of maternal complications but also a high rate of
vertical transmission causing fetal and neonatal
hepatitis4.
Perinatal transmission of HBV occurs if the
mother has had acute HBV infection during late
pregnancy, or if  she is a chronic carrier. Neonatal
contamination does occur during labour and delivery
6.Vertical transmission from chronic carriers exceeds
90% and accounts for up to 40% of the world
carriers in endemic areas6, 7, 8, 9.
If contaminated, the neonate becomes a
chronic carrier himself in 80% to 90% of cases and
is prone to cirrhosis and hepatocellular carcinoma in
adult life 6. When the mother is positive for viral
DNA in her serum, transmission rate is estimated at
90%7. If the mother is negative for viral DNA in
the serum, transmission rate is about 10% to 30% 7.
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Similarly, a positive test for Hb e Ag viral protein
which is a marker for patients at high risk for
transmission of the disease indicates the individual
has a high level of the virus8, 9. However, the absence
of e-antigen does not necessarily exclude active viral
replication because; some patients have mutant
viruses that do not give rise to e-antigen. The
disappearance of Hbe Ag and rise in anti-Hbe
antibodies is associated with a decline in vireamia8, 10.
A study done in Canada showed that
hepatitis in pregnancy is not associated with increase
abortion rate, still birth or congenital malformation6.
However, prematurity is likely to increase if hepatitis
is acquired in the last trimester 6. Some studies have
also demonstrated that infants born to mothers with
acute infection during pregnancy have low birth
weights2.
Hepatitis B virus infection in pregnancy
could be detected through the 3-part hepatitis B
blood panel. These includes hepatitis B surface
Antigen (HBsAg), hepatitis B surface Antibody
(HBsAb or anti-Hbs) and hepatitis B core Antibody
(HbcAb or anti-HBc)12. The prevention of HBV
infection among pregnant women should be a major
concern of every reproductive health expert.
Notable agencies such as the United States Preventive
Services Task Force (USPSTF), Centres for Disease
Control (CDC) and Advisory Committee on
Immunization Practices (ACIP) have all strongly
recommended universal HBsAg screening of
pregnant women to prevent perinatal HBV
transmission and Mother-to-child infection of HBV
13.
Despite these strong recommendations
based on good evidence in maternal-fetal medical
practice, several heath care centers in developing
nations of the world, including Nigeria, are yet to
make HBV screening in pregnancy a routine practice.
Routine screening in pregnancy for some of these
infectious pathogens have been restricted to blood
donors. This has negatively affected the prevention,
diagnosis and early treatment of the infection in
pregnancy.
It is true that in resource -constrained
countries like Nigeria, adopting and implementing a
new preventive measure requires not only the proof
of the existence of the infection but also its
magnitude and the trend of the problem in the
community11. This also includes the implication of
not adopting timely intervention measures11.
Although, some studies on sero-prevalence of HBV
infection in pregnancy have been done in Nigeria,
few have taken place in secondary health care centers
in the Southern region of  the country.
There is need therefore to assess the current
prevalence and the trend in the spread of the
infection. This study was thus designed to assess the
sero-prevalence of HBsAg in pregnancy in a
secondary health care facility in South-South, Nigeria.
Methods
Study setting and design
The study was carried out at the Sacred Heart
Hospital (SHH) Obudu, Cross-River State, Nigeria.
Obudu is an urban community whose inhabitants
are civil servants, students, traders and farmers. The
SHH is the largest in the area and offers clinical
services ranging from primary to secondary care.
The center also provides service to patients from
neighboring Local Government Areas (LGAs) to
Obudu LGA in Cross-River State. This was a
descriptive study carried out from 1st January to 30th
June 2010.
Subjects
 A total of 836 subjects who attended the antenatal
booking clinic and consented were recruited serially
into the study by the researcher. They were offered
pre and posttest counseling by trained antenatal
nurses.
Ethical approval
The hospital gave ethical clearance and approval for
the study to be conducted.
Procedure
During the initial antenatal investigation, five milliliters
of blood was taken from each subject for HBsAg
test by laboratory scientist. The blood samples were
code-labelled to ensure confidentiality. After
centrifugation, the samples were analyzed at the
hospital laboratory for HBsAg. The test was
performed using a rapid Enzyme Linked
immunosorbent Assay (ELISA) with test kit by
Biotec Lab Ltd, Ipswich, Suffolk, IP5 3TP UK; in
accordance with the manufacturer’s instructions. All
reactive samples were further tested with HBV
ELISA kit from DIA-PRO Diagnostic Bioprobes
Srl via columella, Italy. Those who remained reactive
were considered positive for HBV. All subjects,
irrespective of their sero-status were offered post -
test counselling.
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Data analysis
Data collected included the serological status of
subjects studied and their socio-demographic
characteristics. This was done through the use of  a
proforma. The variables of  sero-positive subjects were
analyzed using EPI Info Statistical software Version
3.2.2.
Results
Eight hundred and thirty six (836) subjects were
screened for HBsAg, out of which 55(6.6%) tested
positive (table 1).
The mean age and parity of sero-positive subjects were
26.9 ±5.0 years (range 18-38 years) and 2.2 ± 1.2 (0
to 5) respectively. The age group mostly affected was
24 to 28 year old. Thirty two point seven percent
(32.7%) had secondary level of education, 12.7%
primary, 30.9% tertiary and 23.7% did not have any
formal education. Farmers constituted 29.1%, civil
servants 23.6%, traders 20.0%, students 14.5%,
teachers 5.5% and others 7.3% (table 2).





Table 2: Socio-demographic features of  HBsAg
positive subjects






















Figure 1 Shows the prevalence of HBsAg among pregnant
women in some parts of south -south zone in Nigeria,
namely Benin-city (2.2%), Port-Harcourt (4.3%) and Obudu
(6.6%). Figure 2 demonstrates regional variations among
the three zones out of  the six in the country. The south-
east represented by Enugu reported 4.3%, south-west
represented by Lagos reported 6.08% and south-south
represented by Obudu reported 6.6%. This showed a
relatively higher prevalence in south-south zone in Nigeria.
Figure 1: Sero-prevalence of HBV in some
urban centers in South-South Nigeria
Key: S-East (Enugu), S-West (Lagos) and S-South
(Obudu).
Figure 2: Comparison of sero-prevalence of
HBV among three centers in the various zones
in Southern part of  Nigeria
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Discussion
The sero-prevalence rate of HBV Infection in
pregnancy in the study was 6.6%. This is higher than
the prevalence of 2.2% reported in Benin City11,
4.6% in Enugu14 and 4.3% in Port-Harcourt15. The
prevalence, though higher, is comparable with the
6.08% reported in Lagos16, Nigeria.
On the international scene, studies have
reported various prevalence rates among pregnant
women. In Brazil, a prevalence of 1.64%, France
0.29%, Italy 1.1%, Saudi Arabia 2.44%, Pakistan
4.6%, India 2.3%, and Turkey 2.1%. In the Persian
Gulf, rates of 7.1% have been reported in Oman
and 1.5% in United Arab Emirate. In Africa, rates
of  3% to 4% have been reported in Tunisia, 5.6% in
Sudan and an astronomically high rate of 25% in
Zimbabwe 2, 17-20.
Comparing the rate of 6.6% in this study
which was carried out at Obudu, with the 2.2% in
Benin (reportedly carried out eight years ago) and
4.3% in Port-Harcourt (reportedly carried out five
years ago) there is obviously a rising trend of HBV
infection among pregnant women in the south-south
zone of Nigeria. The recent prevalence in the South
–South zone which is reported in this study is also
higher than that of the South- East (represented by
Enugu) and South- West (represented by Lagos)
zones of  the country. This is an indication that there
is an urgent need to implement intervention measures
by stake holders in the health sector to halt and
reverse the unfortunate trend of  events.
Another important concern demonstrated
in the study is the infection of teenage primigravid
women. The acquisition of HBV infection among
this group of women may most likely be through
heterosexual contacts, given that the age at coitarche
has reduced over the years. Rabiu et al. in a study of
risk factors for hepatitis B virus infection among
pregnant women in Lagos, Nigeria, reported that
early age at sexual debut below 19 years was a
significant contributor 16. Furthermore, more babies
at risk of acquiring the infection are likely to be born
through these young women who are just beginning
their reproductive career.  The finding that infection
was more among women who either had none or
low level of  formal education and were mostly
involved in agricultural /commercial activities could
suggest risky social behavioral practices as a possible
means of contacting the infection.
Several studies have shown that screening
of pregnant women for HBV infection on the basis
of the presence of risk factors may not be effective
14. Hence routine screening is advocated based on
the recommendation of WHO and CDC12-15.
Immunization has been found to be the most
effective way of controlling HBV21. The vaccine has
an outstanding record of  safety and efficacy, and it
is 95% effective in preventing development of the
chronic carrier state 21. It is advisable that infants born
to HBsAg-positive mothers should receive hepatitis
B vaccine and 0.5ml HBIG within 12 hours of birth.
The infected mothers were advised to strictly comply
with this recommendation inoder to reduce the risk
of their babies being infected after birth.
Pregnancy has not been shown to be a
contraindication for vaccination for HBV2. No
apparent risk for adverse effects to the developing
fetus has been demonstrated when HBV vaccine was
administered to pregnant women even in early
pregnancy2. Therefore, those pregnant women who
are identified to be at risk for HBV infection during
pregnancy should be vaccinated2. With studies
showing that lamivudine therapy for HBV in
pregnancy can effectively reduce the risk of
intrauterine infection, its use in resource rich -settings
may also be helpful in preventing maternal-infant
HBV transmission22-26. Studies had not shown that
vaccination of women who are already infected
could be helpful in preventing vertical transmission.
Thus, the women who tested positive to HbsAg were
not vaccinated; they were however sent to liver
specialist for expert medical care.
Conclusion
With the rising trend in HBV infection among
pregnant women in the south-south region of the
country, health education of  the public that is aimed
at the modification of risky social lifestyle, routine
screening of pregnant women, and immunization
of those at risk and mass vaccination of infants
irrespective of maternal HBV status is hereby
recommended. In this way, HBV infection, including
maternal-fetal transmission may be reduced
remarkably.
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